1. Home
  2. NAGA Academy
  3. Should You Buy MedLife Stock (M) in 2025?

Should You Buy MedLife Stock (M) in 2025?

Evaluating MedLife’s robust earnings growth forecast, expanding healthcare services, balanced financial health, and market position to guide your 2026 investment decision.

5 minutes

Intermediate

November 11, 2025

Share the article:

Cristian Cochintu

Cristian Cochintu

Should You Buy MedLife Stock (M) in 2025?

MedlLfe (M) is a leading Romanian healthcare services provider, with over 28,000 services accessed daily and a broad range of preventive and medical services. Positioned strongly in Romania’s private healthcare sector, MedLife may represent an attractive growth and income investment option for 2026.

With NAGA, you can buy MedLife shares (M) with 0% commission (*T&Cs apply) to benefit from potential capital appreciation and strategic exposure to healthcare industry.

Why Invest in MedLife Stock (M) – Key Takeaways 

  • Strong growth forecast: MedLife’s earnings are forecasted to grow by over 77% annually, with revenues expanding around 10.8%, indicating significant growth potential.
  • Healthcare market leader: MedLife is a top private healthcare provider in Romania with increasing patient numbers and service diversification.
  • Balanced financial position: The company maintains solid operational cash flows and prudent debt management underpinned by steady revenue growth.
  • Investing empowerment: Buy M shares to benefit from equity ownership rights, potentially yielding capital gains aligned with healthcare sector growth.

Alternatively, you can copy the moves of top performing traders in real-time with NAGA Autocopy.

Buy MedLife Stock   Practice on Demo   Copy Lead Traders

Overview of MedLife Stock (BVB: M) 

Founded in 1995, Medlife is Romania’s largest private healthcare network, offering services across diagnostics, outpatient care, and medical consultations, supporting the country’s rising healthcare demand. It has become a vital player in digital health transformation and expanding medical accessibility.

MedlLfe is listed on the Bucharest Stock Exchange (BVB) and included in the BET Index, which tracks the performance of the most liquid Romanian companies, with approximately 43% free float and a diverse shareholder base. The company plays a crucial role in Romania's evolving healthcare ecosystem.

  • Ticker: M (Bucharest Stock Exchange)
  • Ownership: Mixed institutional and retail shareholders
  • Public float: Approximately 43% freely traded
  • Sector: Healthcare Services – Private Medical Care
  • Employees: ~ 3,000

Thanks to its strong market position and expanding service portfolio, MedLife stock is considered one of the top 10 Romanian stocks for 2026 and beyond.

MedLife Stock Analysis and Forecasting

MedLife stock (BVB: M) may be an attractive investment option for several reasons, including:

Strong earnings growth forecast 

The company’s earnings per share (EPS) are expected to grow by about 77.5% annually over the next three years, supported by revenue growth of approximately 10.8% per year. This solid growth outlook is underpinned by rising healthcare demand and successful integration of new service lines.

Revenue and patient growth 

MedLife continues expanding its huge customer base, while increasing operating volumes and investing in medical infrastructure, fueling medium-term financial gains.

Financial health 

The company sustains positive operating cash flow and manageable debt levels, reflecting prudent financial management. Its cost structure and margin improvement support ongoing profitability growth despite competitive pressures.

MedLife stock chart pattern 

MedLife’s stock price has shown resilience in 2025 exhibiting a symmetrical triangle pattern on the H4 chart, which signifies price consolidation and typically precedes a breakout in either direction, best confirmed by rising volume. The current RSI is neutral and momentum is balanced, so traders should watch for a decisive move above or below the triangle boundaries for future direction. This setup usually suggests an imminent trend change; monitoring volume spikes and a breakout will be crucial to determining possible targets. 

Medlife stock chart pattern
MedLife Transilvania Stock H4 Chart (Source: NAGA Web App)

Past performance is not a reliable indicator of future results. All historical data, including but not limited to returns, volatility, and other performance metrics, should not be construed as a guarantee of future performance.

Technical traders using the NAGA Web App can leverage real-time charts, indicators, and automated alerts to time entries and exit.

Bullish MedLife stock price forecast

Analysts’ price targets for MedLife vary, with median forecasts around 7.06 RON, with possible ranges between 6.67 and 7.40 RON for the next 12 months. Market volatility and healthcare sector factors could influence actual pricing outcomes.

Important: When considering MedLife's fundamental analysis, financial rating and price predictions, it’s important to remember that high market volatility and a changing economic environment make long-term estimates difficult. As such, analysts and algorithm-based platforms can and do get their ratings and predictions wrong. Always do your own research before making an investment decision. And never trade or invest more than you can afford to lose.

How to invest in MedLife (M) stock?

On NAGA, you can open an Invest Account to directly purchase MedLife shares (M) as well as a wide range of stocks listed on BET Index. Owning shares grants dividend rights and voting privileges, potentially suitable for long-term investors focused on compounding wealth through stock appreciation and income.

How to invest in MedLife (M) stock?
MedLife Stock H1 Chart (Source: NAGA Web App)

Past performance is not a reliable indicator of future results. All historical data, including but not limited to returns, volatility, and other performance metrics, should not be construed as a guarantee of future performance.

How to get started with MedLife stock on NAGA 

Here is how to buy MedLife (M) stock with NAGA, a trademark of The NAGA Group AG, a German-based FinTech company publicly listed on the Frankfurt Stock Exchange: 

  1. Create an account – Open an Invest account for full stock ownership.
  2. Complete the verification – Complete the KYC verification for compliance.
  3. Deposit funds – Add RON, EUR, USD, or other supported currencies.
  4. Search for the “MedLife” or “MDL_D” Ticker – Access MedLife shares on the platform.
  5. Take your position – Place orders to buy MedLife shares.
  6. Manage your portfolio – Use NAGA’s portfolio tracking, social trading, and risk management tools

Buy MedLife stock   Practice on demo   Copy lead traders

Should you buy MedLife (M) stock today?

MedLife’s focus on service expansion, digital health, and strong earnings growth forecasts make it a compelling candidate for investors seeking exposure to Romania’s private healthcare sector. Consider your investment horizon and risk tolerance, as sector evolution and economic factors may impact stock performance.

Direct ownership of MedLife stock offers distinct advantages to leverage company’s potential within your investment strategy.

Free resources 

Before you start investing in MedLife shares, you should consider using the educational resources we offer like NAGA Academy or a demo trading account. NAGA Academy has lots of free trading courses for you to choose from, and they all tackle a different financial concept or process – like the basics of analyses – to help you to become a more informed trader. 

Our demo account is a great place for you to learn more about leveraged trading, and you’ll be able to get an intimate understanding of how CFDs work – as well as what it’s like to trade with leverage – before risking real capital. For this reason, a demo account with us is a great tool for investors who are looking to make a transition to leveraged trading. 

Sources:

FAQs about MedLife Stock (M)

MedLife offers robust earnings growth forecasts, expanding patient base, and improving financial metrics, making it potentially attractive to stock investors for 2026.

This information prepared by naga.com is not an offer or a solicitation for the purpose of purchase or sale of any financial products referred to herein or to enter into any legal relations, nor an advice or a recommendation with respect to such financial products. This information is prepared for general circulation. It does not have regard to the specific investment objectives, financial situation or the particular needs of any recipient. You should independently evaluate each financial product and consider the suitability of such a financial product, by taking into account your specific investment objectives, financial situation or particular needs, and by consulting an independent financial adviser as needed, before dealing in any financial products mentioned in this document. This information may not be published, circulated, reproduced or distributed in whole or in part to any other person without the Company’s prior written consent. Past performance is not always indicative of likely or future performance. Any views or opinions presented are solely those of the author and do not necessarily represent those of NAGA.
RISK WARNING: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 77.41% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.